GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » EV-to-EBIT

SSY Group (HKSE:02005) EV-to-EBIT : 9.19 (As of May. 02, 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SSY Group's Enterprise Value is HK$15,713 Mil. SSY Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,709 Mil. Therefore, SSY Group's EV-to-EBIT for today is 9.19.

The historical rank and industry rank for SSY Group's EV-to-EBIT or its related term are showing as below:

HKSE:02005' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.32   Med: 16.84   Max: 33.07
Current: 9.32

During the past 13 years, the highest EV-to-EBIT of SSY Group was 33.07. The lowest was 8.32. And the median was 16.84.

HKSE:02005's EV-to-EBIT is ranked better than
77.96% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.56 vs HKSE:02005: 9.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SSY Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$16,762 Mil. SSY Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,709 Mil. SSY Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 10.20%.


SSY Group EV-to-EBIT Historical Data

The historical data trend for SSY Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group EV-to-EBIT Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.27 18.78 13.63 9.88 9.81

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.63 - 9.88 - 9.81

Competitive Comparison of SSY Group's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SSY Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SSY Group's EV-to-EBIT falls into.



SSY Group EV-to-EBIT Calculation

SSY Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15713.384/1708.982
=9.19

SSY Group's current Enterprise Value is HK$15,713 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,709 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group  (HKSE:02005) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SSY Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1708.982/16762.0956
=10.20 %

SSY Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$16,762 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,709 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SSY Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines